UPSTREAM BIO, INC. Payments to Acquire Short-term Investments
UPSTREAM BIO, INC. (UPB) reported Payments to Acquire Short-term Investments of $65.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-11
- UPSTREAM BIO, INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was $50.94M, a 10.76% decline year-over-year.
- UPSTREAM BIO, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $14.42M, a 94.58% decline year-over-year.
- UPSTREAM BIO, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $38.28M, a 9.30% decline year-over-year.
- UPSTREAM BIO, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $24.46M, a 66.68% decline year-over-year.
- UPSTREAM BIO, INC. payments to acquire short-term investments for fiscal 2025 was $385.88M, a 32.78% increase from fiscal 2024.
- UPSTREAM BIO, INC. payments to acquire short-term investments for fiscal 2024 was $290.61M, a 125.30% increase from fiscal 2023.
- UPSTREAM BIO, INC. payments to acquire short-term investments for fiscal 2023 was $128.99M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $65.36M 10-Q · filed 2026-08-11 | $103.64M derived: sum of 3 quarters · filed 2026-08-11 | $128.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $14.42M 10-Q · filed 2026-05-13 | $52.70M derived: sum of 2 quarters · filed 2026-05-13 | $77.16M derived: sum of 3 quarters · filed 2026-05-13 | $134.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $38.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $62.74M derived: sum of 2 quarters · filed 2026-03-26 | $119.82M derived: sum of 3 quarters · filed 2026-08-11 | $385.88M 10-K · filed 2026-03-26 |
| 2025-09-30 | $24.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $81.54M derived: sum of 2 quarters · filed 2026-08-11 | $347.60M 10-Q · filed 2025-11-05 | $389.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $57.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $323.14M 10-Q · filed 2026-08-11 | $365.35M derived: sum of 3 quarters · filed 2026-08-11 | $438.75M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $266.06M 10-Q · filed 2026-05-13 | $308.26M derived: sum of 2 quarters · filed 2026-05-13 | $381.67M derived: sum of 3 quarters · filed 2026-05-13 | $533.25M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $42.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $115.61M derived: sum of 2 quarters · filed 2026-03-26 | $267.20M derived: sum of 3 quarters · filed 2026-03-26 | $290.61M 10-K · filed 2026-03-26 |
| 2024-09-30 | $73.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $224.99M derived: sum of 2 quarters · filed 2025-11-05 | $248.40M 10-Q · filed 2025-11-05 | $283.20M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $151.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $175.00M 10-Q · filed 2025-08-06 | $209.79M derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | $23.41M 10-Q · filed 2025-05-06 | $58.21M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $34.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $128.99M 10-K · filed 2025-03-12 | ||
| 2023-09-30 | $94.19M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |